Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and osteoarthritis.

The company's research activities and products are connected by a common thread focused on the provision of tailored treatments that work on the body's own terms to enable doctors to combat numerous diseases and medical conditions.

The company has gained international recognition over the last 20 years for the creation of inventive medications that improve the quality of life of children and adults all around the world.

Ferring has its own production facilities in several European countries, in South America, Israel and China and is currently building new facilities in the US and India. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing.

Ferring's marketing, medical services and sales teams, led by corporate headquarters in Saint-Prex, Switzerland, operate from more than 50 countries and employ more than 4500 people throughout the world, while treatments are available in more than 90 countries. This expansion has allowed Ferring to maintain a double digit annual growth rate over the last two decades.

Ferring's R&D projects complement Ferring's product portfolio and will add a new generation of products to some of the company's most successful specialty brands. R&D facilities are located in Denmark, USA, Israel, India and China. 

Ferring is committed to a future where it will continue to provide new and innovative medicines by utilising existing and acquired skills and the development of pioneering technologies and, where necessary, through partnerships with academic institutes and other companies.